MedTrace Logo

A Phase II Study of Dacomitinib in Progressive Brain Metastases

NCT02047747 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2016-09-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the disease response, survival, and side effects of an experimental drug called dacomitinib in progressive brain metastases.

Conditions

Interventions

DRUG

Dacomitinib

Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • David Piccioni, M.D., Ph.D

    lead OTHER

Principal Investigators

  • David Piccioni, M.D., Ph.D. · University of California Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02047747 on ClinicalTrials.gov